Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 6, 2024
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025
Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)
Read more at globenewswire.com
